Journal: Matrix Biology Plus
Article Title: Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker
doi: 10.1016/j.mbplus.2020.100021
Figure Lengend Snippet: TNX protein level in tumoral versus normal tissues. Cancers of high incidence/mortality were studied (upper part), as well as cancers for which TNX status was previously studied (lower part) thanks to TNX immunolabelling of tissue sections on Tissue MicroArray slides (#MC6163 and #T392a). A: Representative cores of normal (left) and tumoral (right) tissues. Scale bar = 100 μm. B: Quantification of stromal TNX staining intensity. A segmentation between stromal and epithelial areas was performed, followed by measurement of reciprocal mean grey value (staining intensity) in the stromal area. Segmentation training was newly perfomed for each spot. Mann-Whitney test was performed between normal and tumoral conditions (****p < 0.0001; ***p < 0.001; **p < 0.01 and *p < 0.05). C: Clinical sample scoring. Staining was blindly scored according to 4 categories: negative, low, intermediate and high. Results are presented as percentage of total cores for each cancer type.
Article Snippet: Supplementary Fig. S5 TNX immunostaining on pan-cancer Tissue Microarray Commercial pan-cancer Tissue Microarray ( US Biomax #MC6163 ) was immunostained for TNX protein.
Techniques: Microarray, Staining, MANN-WHITNEY